Viking Therapeutics is more than just a weight-loss stock, and that’s drawing cheers
The biotech’s liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.
The biotech’s liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.
